MA-VERACODE
23.5.2023 17:27:28 CEST | Business Wire | Press release
Veracode, a leading provider of intelligent software security solutions, has been positioned as a 10-time Leader in the 2023 Gartner Inc. Magic Quadrant for Application Security Testing—an in-depth evaluation of the market’s competitors. The company has been recognized as a Leader in the report every single time since it was first published.
With independent feedback and ratings from customer reviews culminating in a 97 percent “willingness to recommend” (based on 61 reviews, as of 31 July 2022), Veracode was also positioned as a Gartner Peer Insights™ Customers’ Choice for Application Security Testing.
Sam King, Chief Executive Officer at Veracode, said, “For more than 17 years, we have had an unrelenting commitment to making secure software a competitive advantage for our customers. Our continued position as a Leader in the Gartner Magic Quadrant, combined with our recognition as a Customers’ Choice, we feel demonstrates the trust placed in us every day by developers, security teams, and business leaders worldwide. We are proud to say that Veracode was one of the pioneers of application security and now we are propelling the category into the future: intelligent software security.”
The Head of Application Security at a banking company reviewing Veracode in Gartner Peer Insights™ said, “Of all the companies that carry out POCs (Proof of Concepts)...only Veracode proves to be a solid and senior company or enough to put in our financial institution." A security analyst at another firm commented, “In order for a product to be successful, it needs to do two things right, ‘product performance’ and ‘support’. Veracode gives you the best of both worlds, a great product with great support.”
Protecting the Software Supply Chain
Veracode offers EU and UK Support through its dedicated European Region, an EU instance that allows European organizations to address data residency concerns. The company has also achieved the US Federal Risk and Authorization Management Program (FedRAMP), which makes multiple tools available to US federal agencies that want to find and fix software supply chain vulnerabilities in accordance with compliance mandates. Veracode is the only software composition analysis vendor listed in the FedRAMP marketplace.
King said, “Increased reliance on third-party code, along with emerging regulations for software security and data compliance, are some of our customers’ greatest challenges. To alleviate the pressure on organizations, our proprietary database tracks open-source risk and our platform provides continuous scanning through multiple tools, including container security, infrastructure-as-code (IaC) scanning, and Software Bill of Materials (SBOM) capabilities.”
Veracode’s recent addition of Peer Benchmarking—a new self-service capability that allows organizations to measure their flaw and remediation performance against industry peers—also enables security leaders to assess the impact of their investments and demonstrate value to the business.
Strength of Vision: Delivering Capabilities Against Customer Needs
In the past year, Veracode has also made two significant acquisitions, to which the company credits its position in the report. Firstly, the acquisition of the Germany-based Crashtest Security tool enhanced Veracode’s existing dynamic analysis and penetration testing capabilities for web apps and application programming interfaces (APIs), as well as broadening customer access globally. More recently, the acquisition of auto-remediation technology from Jaroona, a 2021 Gartner® Cool Vendor™ for DevSecOps, enabled the launch of Veracode Fix. The new AI-powered product automatically suggests remediations for security flaws found in code and open-source dependencies.
Brian Roche, Chief Product Officer at Veracode, said, “One of the biggest pain points our customers express is mitigating intensifying threat against an expanding attack surface, while accelerating development velocity and minimizing costs. We’ve invested heavily in our platform over the past year to develop automated solutions that remove friction for developers and provide security teams with a comprehensive view of risk. The launch of Veracode Fix addresses the need to broaden our focus from application security testing to intelligent software security.”
To download a complimentary copy of the full 2023 Gartner Magic Quadrant Report, visit the Veracode website.
To learn more about intelligent software security from Veracode, please visit: https://www.veracode.com/products
1Gartner, Magic Quadrant for Application Security Testing, Mark Horvath, Dale Gardner, Manjunath Bhat, Ravisha Chugh, Angela Zhao, 17 May 2023.
2Gartner, “Peer Insights ‘Voice of the Customer’: Application Security Testing” by Peer Contributors, September 30, 2022.
Gartner does not endorse any vendor, product or service depicted in our research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, Magic Quadrant, Cool Vendors and PEER INSIGHTS are registered trademarks of Gartner, Inc. and/or its affiliates and are used herein with permission. All rights reserved.
About Veracode
Veracode is intelligent software security. The Veracode Software Security Platform continuously finds flaws and vulnerabilities at every stage of the modern software development lifecycle. Prompted by powerful AI trained by trillions of lines of code, Veracode customers fix flaws faster with high accuracy. Trusted by security teams, developers, and business leaders from thousands of the world’s leading organizations, Veracode is the pioneer, continuing to redefine what intelligent software security means.
Copyright © 2023 Veracode, Inc. All rights reserved. Veracode is a registered trademark of Veracode, Inc. in the United States and may be registered in certain other jurisdictions. All other product names, brands or logos belong to their respective holders. All other trademarks cited herein are property of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005707/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse
Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe
Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release
Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
